At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|November 10, 2022
Update on adjuvant treatment of bladder cancer
Author(s)Urology Times staff
“The bar is high; we want to be curing these patients, not just delaying a recurrence of their cancer,” says Arlene O. Siefker-Radtke, MD.
Advertisement
In this video, Arlene O. Siefker-Radtke, MD, discusses recent developments in the adjuvant treatment of bladder cancer. Siefker-Radtke is a professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston. She was interviewed at the
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5